title: p53-based therapeutics for head and neck squamous cell carcinoma.
abstract: Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Tassone
authors.forename: Matthew
authors.initials: M
authors.lastname: Old
authors.forename: Theodoros N
authors.initials: TN
authors.lastname: Teknos
authors.forename: Quintin
authors.initials: Q
authors.lastname: Pan
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D009154:Mutation; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D016159:Tumor Suppressor Protein p53
keywords: Anti-cancer therapeutics; Gene therapy; Head and neck cancer; Human papillomavirus; Oral cancer; Tumor suppressor gene; p53